ANIP - ANI Pharmaceuticals Non-GAAP EPS of $0.76 beats by $0.09 revenue of $94.2M beats by $8.06M

2023-03-09 06:52:38 ET

• ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q4 Non-GAAP EPS of $0.76 beats by $0.09 .
• Revenue of $94.2M (+54.7% Y/Y) beats by $8.06M .
• Cash and cash equivalents were $48.2 million, net accounts receivable was $165.4 million, and face value of debt was $297.0 million as of December 31, 2022.
• 2023 Guidance:

  - Total Company expected Net Revenues between $360.0 million and $385.0 million, vs consensus of $352.43M representing approximately 14% to 22% growth as compared to $316.4 million recognized in 2022;

  - Cortrophin specific revenue guidance between $80.0 million to $90.0 million, representing 92% to 116% growth as compared to $41.7 million recognized in 2022;

  - Total Company non-GAAP Gross Margin between 59.5% and 61.0%;

  - Total Company Adjusted non-GAAP EBITDA between $78.0 million and $88.0 million; and

  - Adjusted non-GAAP Diluted Earnings per Share between $2.09 and $2.59.

  In addition, we currently anticipate between 16.8 million and 17.1 million shares outstanding and an effective tax rate of approximately 24% prior to any federal tax reform

For further details see: